Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Recent & Breaking News (NDAQ:PMN)

Glass Lewis Recommends ProMIS Neurosciences Shareholders Vote for the Share Consolidation at the Upcoming Special Meeting

GlobeNewswire November 2, 2021

ProMIS Neurosciences Announces Update to Senior Management Team

GlobeNewswire October 22, 2021

ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors

GlobeNewswire October 22, 2021

ProMIS Neurosciences Files Special Meeting Proxy Material

GlobeNewswire October 21, 2021

ProMIS Neurosciences Announces Special Shareholder Meeting

GlobeNewswire October 7, 2021

ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021

GlobeNewswire September 15, 2021

ProMIS Neurosciences (TSX:PMN) to Present at Undruggable Leaders Forum

Brieanna McCutcheon  September 15, 2021

ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference

GlobeNewswire September 13, 2021

ProMIS Neurosciences (TSX:PMN) appoints accomplished biotechnology executive

Brieanna McCutcheon  September 1, 2021

ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors

GlobeNewswire September 1, 2021

ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering

GlobeNewswire August 25, 2021

ProMIS Neurosciences (TSX:PMN) upsizes public offering

Trevor Abes  August 18, 2021

ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M

GlobeNewswire August 18, 2021

IIROC Trade Resumption - PMN

PR Newswire August 18, 2021

ProMIS Neurosciences Inc. Announces Pricing of US$15 Million Public Offering of Units

GlobeNewswire August 18, 2021

IIROC Trading Halt - PMN

PR Newswire August 17, 2021

ProMIS Neurosciences (TSX:PMN) announces US$15M offering

John Ballem  August 17, 2021

ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units

GlobeNewswire August 17, 2021

ProMIS Neurosciences Announces Second Quarter 2021 Results

GlobeNewswire August 12, 2021

ProMIS Neurosciences Issues Chairman's Memorandum

GlobeNewswire August 4, 2021